1.Breakthrough in heart failure with preserved ejection fraction: are we there yet?.
Shir Lynn LIM ; Carolyn Su Ping LAM
The Korean Journal of Internal Medicine 2016;31(1):1-14
Heart failure with preserved ejection fraction (HFPEF) is a global health problem of considerable socioeconomic burden. It is projected to worsen with the aging population worldwide. The lack of effective therapies underscores our incomplete understanding of this complex heterogeneous syndrome. A novel paradigm has recently emerged, in which central roles are ascribed to systemic inflammation and generalized endothelial dysfunction in the pathophysiology of HFPEF. In this review, we discuss the role of the endothelium in cardiovascular homeostasis and how deranged endothelial-related signaling pathways contribute to the development of HFPEF. We also review the novel therapies in various stages of research and development that target different components of this signaling pathway.
Animals
;
Endothelium, Vascular/*physiopathology
;
Heart Failure/diagnosis/metabolism/*physiopathology/therapy
;
Humans
;
Inflammation/diagnosis/metabolism/*physiopathology/therapy
;
Inflammation Mediators/metabolism
;
Prognosis
;
Risk Factors
;
Signal Transduction
;
*Stroke Volume
;
*Ventricular Function, Left
2.Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction.
Glenn K M LEE ; Li-Ching LEE ; Christopher W Y LIU ; Shir Lynn LIM ; Lu-Ming SHI ; Hean-Yee ONG ; Yean-Teng LIM ; Tiong-Cheng YEO
Annals of the Academy of Medicine, Singapore 2010;39(3):163-167
INTRODUCTIONThe Framingham Risk Score (FRS) is a well-validated epidemiologic tool used to assess the risk for a fi rst cardiac event. Because young patients presenting with a fi rst myocardial infarction (MI) tend to have less significant risk profiles compared with older patients, we hypothesized that FRS may underestimate cardiac risk in these patients.
MATERIALS AND METHODSWe studied 1267 patients between January 2002 and November 2007 presenting with a fi rst MI. Patients with pre-existing diabetes mellitus and vascular disease were excluded. FRS was calculated for each patient. Patients were divided based on their age: group A (<40 years), group B (40 to 64 years) and group C (> or =65 years).
RESULTSThe mean age was 54.7 +/- 11 years, 88.4% of the patients were males. Younger patients were more likely to be assigned with lower scores. Based on FRS, 63.0%, 29.3% and 14.2% of group A, B and C patients were classified as low risk (10-year risk for cardiac events<10%) respectively, P <0.001. The sensitivity of FRS in identifying at least intermediate risk subjects (10-year risk for cardiac events >10%) was 37.0% in group A vs 85.8% in group C (P <0.001). The incidence of newly diagnosed diabetes mellitus was higher in younger patients (12.0% vs 13.2% vs 7.1 % in groups A, B and C respectively, P = 0.027).
CONCLUSIONSFRS inadequately predicts cardiac risk in young patients presenting with a fi rst MI. This could be because a significant proportion of these young patients have undiagnosed diabetes mellitus, a coronary artery disease risk equivalent.
Adult ; Age Factors ; Aged ; Algorithms ; Diabetes Complications ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; complications ; diagnosis ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Sex Factors
3.Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
Jonathan YAP ; Mun Yee THAM ; Jalene POH ; Dorothy TOH ; Cheng Leng CHAN ; Toon Wei LIM ; Shir Lynn LIM ; Yew Woon CHIA ; Yean Teng LIM ; Jonathan CHOO ; Zee Pin DING ; Ling Li FOO ; Simin KUO ; Yee How LAU ; Annie LEE ; Khung Keong YEO
Annals of the Academy of Medicine, Singapore 2022;51(2):96-100
INTRODUCTION:
Despite reports suggesting an association between COVID-19 mRNA vaccination and pericarditis and myocarditis, detailed nationwide population-based data are sparsely available. We describe the incidence of pericarditis and myocarditis by age categories and sex after COVID-19 mRNA vaccination from a nationwide mass vaccination programme in Singapore.
METHODS:
The incidence of adjudicated cases of pericarditis and myocarditis following COVID-19 mRNA vaccination that were reported to the vaccine safety committee between January to July 2021 was compared with the background incidence of myocarditis in Singapore.
RESULTS:
As of end July 2021, a total of 34 cases were reported (9 pericarditis only, 14 myocarditis only, and 11 concomitant pericarditis and myocarditis) with 7,183,889 doses of COVID-19 mRNA vaccine administered. Of the 9 cases of pericarditis only, all were male except one. The highest incidence of pericarditis was in males aged 12-19 years with an incidence of 1.11 cases per 100,000 doses. Of the 25 cases of myocarditis, 80% (20 cases) were male and the median age was 23 years (range 12-55 years) with 16 cases after the second dose. A higher-than-expected number of cases were seen in males aged 12-19 and 20-29 years, with incidence rates of 3.72 and 0.98 case per 100,000 doses, respectively.
CONCLUSION
Data from the national registry in Singapore indicate an increased incidence of pericarditis and myocarditis in younger men after COVID-19 mRNA vaccination.
Adolescent
;
Adult
;
COVID-19/prevention & control*
;
COVID-19 Vaccines/adverse effects*
;
Child
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myocarditis/etiology*
;
Pericarditis/etiology*
;
RNA, Messenger
;
SARS-CoV-2
;
Vaccination/adverse effects*
;
Vaccines, Synthetic
;
Young Adult
;
mRNA Vaccines
4.Low incidence of cardiac complications from COVID-19 and its treatment among hospitalised patients in Singapore.
Tony Yi Wei LI ; Jinghao Nicholas NGIAM ; Nicholas W S CHEW ; Sai Meng THAM ; Zhen Yu LIM ; Shuyun CEN ; Shir Lynn LIM ; Robin CHERIAN ; Raymond C C WONG ; Ping CHAI ; Tiong Cheng YEO ; Paul Anantharajah TAMBYAH ; Amelia SANTOSA ; Gail Brenda CROSS ; Ching Hui SIA
Annals of the Academy of Medicine, Singapore 2021;50(6):490-493
5.Therapeutic temperature management (TTM): post-resuscitation care for adult cardiac arrest, with recommendations from the National TTM Workgroup.
Siew Hon Benjamin LEONG ; Enoch CHAN ; Benjamin Choon Heng HO ; Colin YEO ; Sennen LEW ; Duu Wen SEWA ; Shir Lynn LIM ; Chee Wan LEE ; Pow Li CHIA ; Tien Siang Eric LIM ; Eng Kiang LEE ; Marcus Eng Hock ONG
Singapore medical journal 2017;58(7):408-410
Therapeutic temperature management (TTM) was strongly recommended by the 2015 International Liaison Committee on Resuscitation as a component of post-resuscitation care. It has been known to be effective in improving the survival rate and neurologic functional outcome of patients after cardiac arrest. In an effort to increase local adoption of TTM as a standard of post-resuscitation care, this paper discusses and makes recommendations on the treatment for local providers.